Wedbush Starts PerkinElmer (PKI) at Outperform; Encouraged by Caliper and Push Into Lab IT/Software
Tweet
Share
E-mailGet Alerts PKI Hot Sheet
Price: $115.24 --0%
Rating Summary:
12 Buy, 16 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
12 Buy, 16 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush initiates coverage on PerkinElmer (NYSE: PKI) with an Outperform. PT $34.00.
Analyst, Zarak Khurshid, highlighted points include: 1) Excited by recently acquired growth from in vivo imaging & microfluidics; 2) Refreshed analytical tools portfolio still driving robust applied growth; 3) Encouraged by ahead-of-the curve push into software and informatics; 4) Our 2012 and 2013 revenue estimates are 2.5% above the Street’s (due to higher CALP, imaging, and applied growth assumptions), while our 2012 EPS estimates are $0.02 lower in due to less aggressive 4Q12 loading."
For an analyst ratings summary and ratings history on PerkinElmer click here. For more ratings news on PerkinElmer click here.
Shares of PerkinElmer closed at $27.70 yesterday.
Analyst, Zarak Khurshid, highlighted points include: 1) Excited by recently acquired growth from in vivo imaging & microfluidics; 2) Refreshed analytical tools portfolio still driving robust applied growth; 3) Encouraged by ahead-of-the curve push into software and informatics; 4) Our 2012 and 2013 revenue estimates are 2.5% above the Street’s (due to higher CALP, imaging, and applied growth assumptions), while our 2012 EPS estimates are $0.02 lower in due to less aggressive 4Q12 loading."
For an analyst ratings summary and ratings history on PerkinElmer click here. For more ratings news on PerkinElmer click here.
Shares of PerkinElmer closed at $27.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- RBC Capital Starts Krystal Biotech (KRYS) at Outperform
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
